Titan Spine has achieved 27,000 implantations of its Endoskeleton interbody fusion devices since its inception–an increase of 25% from 2013–and has recorded a US$26m annualised sales revenue run-rate. A company press release states that these figures reflect a significant growth over the past year with the continuing adoption of its spinal interbody fusion devices featuring proprietary surface technology by surgeons.
Kevin Gemas, president of Titan Spine, commented, “Over the past year, Titan achieved several milestones that attributed to our global growth and further validated our position as the leader in surface technology. These include the expanded use of our devices in Europe, securing market registration approval in Australia and New Zealand, and obtaining FDA clearance for both the Endoskeleton TL, the first lateral device to feature surface technology, as well as our next generation nanoLOCK surface technology, the first FDA-cleared interbody fusion devices to feature nanotechnology.”
Steve Cichy, vice president of sales of Titan Spine, said, “the science of our surface technology is beginning to resonate deeply within the surgeon and scientific communities.” Titan Spine is now implanting around 7,000 implants per year, with over 220 hospital customers and over 90 US distributors. The company is also planning the full launch of its Endoskeleton TL lateral device as well as another interbody device in Q1 of 2015.
The full line of Endoskeleton devices will feature Titan Spine’s nanoLOCK implant surface technology, consisting of a combination of roughened topographies at the macro, micro, and nano levels. This combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process by promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins, and creating the potential for a faster and more robust fusion. All of the company’s surface technologies are created through a reductive process, which Titan Spine says eliminates the potential for delamination when compared to products with a PEEK-titanium interface.